Herzuma 150 mg powder for concentrate for solution for infusion

A Phase 3 Open-label Trial of Neoadjuvant Trastuzumab Deruxtecan (TDXd) Monotherapy or T-DXd followed by THP Compared to ddAC-THP in Participants with High-risk HER2-positive Early-stage Breast Cancer (DESTINY-Breast11)

A Multicenter, Randomized, Open-Label, Phase 3 Trial of Trastuzumab Deruxtecan (Enhertu®) Plus Chemotherapy Plus or Minus Pembrolizumab versus Chemotherapy Plus Trastuzumab Plus Or Minus Pembrolizumab as First-Line Treatment in Participants with Unresectable, Locally Advanced or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (GEJ) Cancer (DESTINY-Gastric05)